Objective. To evaluate the efficacy of the administration of zidovudine (AZT ), an antiretroviral drug, in patients with primary Sjö gren's syndrome (SS).
Sjö gren's syndrome (SS ) is a chronic, systemic autoorders [9, 10] ; (d ) the description of intracisternal A-type retrovirus particules in salivary gland cells from SS immune disease characterized by lymphocytic infiltration of the exocrine glands [1] . The salivary and lachrymal patients [11, 12] ; (e) the demonstration of a reverse transcriptase activity in salivary glands of SS patients glands are primarily involved, leading to glandular hypofunction and the clinical presentation of dry mouth [12] ; (f ) the identification of an exogenous retroviral sequence from salivary gland tissue of an SS patient (xerostomia) and eyes (keratoconjunctivitis sicca) [1] . It can occur alone (primary SS ) or in association (second- [13] . Animal models also provide supportive evidence: Green et al. [14] described a sialadenitis in the HTLVary SS) with various autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus or 1-tax transgenic mouse and MAIDS mice develop a salivary gland lymphocytic infiltration [7, 8] . myositis [1] . About 30% of primary SS patients exhibit extraglandular manifestations including non-erosive Zidovudine, the first antiretroviral agent approved for clinical use, is a thymidine analogue that inhibits retroarthritis, Raynaud's phenomenon or involvement of thyroid, lungs, kidneys and liver. Five to 10% of the viral replication by interfering with the viral reverse transcriptase and elongation of the viral DNA chain patients will develop a malignant lymphoproliferative disease [1] . [15] . The administration of zidovudine (AZT ) in some patients with diffuse infiltrative lymphocytosis syndrome Retroviruses have been implicated in the aetiology of various autoimmune diseases [2, 3] . Evidence for a (DILS ) and HIV infection led to a diminution of salivary gland enlargement and improvement in the pathogenic role for retroviruses in the initiation and maintenance of autoimmunity in SS includes: (a) the associated discomfort [16 ] . Despite the development of symptomatic therapy, no systemic treatment is still presence in SS patients of antibodies which are crossreactive with retroviral gag proteins [4-6 ]; (b) the available for SS [17] . The aim of the present study was to determine the possible effects of AZT administration detection of retrovirus antigens in SS patients [7] ; (c) the occurrence of SS-like conditions in human immunoon primary SS disease-related signs and symptoms. deficiency virus (HIV ) patients [8] and human T-lymphotropic virus Type I (HTLV-1)-associated dis-
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We designed an open-labelled, uncontrolled longitudinal 4 = severe symptoms unrelieved by AT ); (6) the frequency of AT use; (7) the fatigue evaluation test by a classification criteria for primary SS; (2) disease duration (defined from diagnosis) of <1 yr; (3) evidence of active 0-100 mm visual analogue scale ( VAS); (8) the tender joint count (maximum 24); (9) a muscle tender point disease requiring treatment based on ocular and oral dryness complaints, extraglandular symptoms (including count (maximum 18); (10) psychological status by the Hamilton scale. fatigue, arthralgias, myalgias) and the presence of an active inflammatory process such as an elevated erythroPatient's and physician's global assessments were evaluated by a 0-100 mm VAS. cyte sedimentation rate ( ESR) of >25 mm/h or hypergammaglobulinaemia; (4) a 3 month wash-out period
The ophthalmological assessment was made by the same physician (PD) and consisted of fluorescein tear of any systemic treatment capable of interfering with the condition process. Exclusion criteria were HIV1-2, break-up time test ( TBUT ), Schirmer's test and corneal evaluation by Rose Bengal staining (0-9 score). HTLV-1 and hepatitis C (HCV ) infection, and the presence of any other connective tissue disease. Only Biological parameters were measured monthly during 4 months: ESR, C-reactive protein (CRP), full blood modifications in the symptomatic treatment, such as artificial tears (AT ), were allowed during the study.
count, renal and liver function tests, creatine kinase, serum immunoglobulins A, M and G, antinuclear antiApproval was obtained from the local ethical board and written informed consent from the patients. Seven bodies (ANA) and rheumatoid factor (RF ). An indirect immunofluorescence procedure using Hep2 cells was female patients (age 57 ± 8.6 .. yr) were included in the study. Their clinical, immunological and histological employed to detect the presence and titre of ANA (Immunoconcept, Sacramento, CA, USA). Anti-Ro/ characteristics are summarized in Table 1 were assessed after an extra month of follow-up free of therapy. During the treatment period with AZT, six 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe); (3) the need for water during speaking and the improved and one remained unchanged. Clinical and biological results are summarized in Table 2 . need to awaken for water drinking; (4) the speech test (number of repeated 'Puttica' during 2 min; presented Dry mouth by P. J. Shirlaw at 'New Advances in Basic Science, Diagnosis and Treatment of Sjö gren's Syndrome', Clinical complaints of dry mouth were improved in 7/7 patients (P < 0.001); this was also supported by a reducLondon, January 1997); (5) a dry eye evaluation (0-4 scale: 0 = no symptom, 1 = mild symptoms relieved tion of water absorption for speaking (3/7 patients at depression. The latter was improbable taking into account the Hamilton scale (<10). entry and 0/7 after 3 months) and during the night (6/7 to 1/7). In addition, the speech test performance was AZT administration was well tolerated, except for mild and transitory gastrointestinal side-effects. AZT also ameliorated at 2 min (130 ± 26 to 210 ± 34, P < 0.02).
appears to be safe and better tolerated than the other proposed drugs for SS, such as cyclosporin . This is, to our knowledge, the second HIV-unrelated disease which has Similarly, a subjective improvement (P < 0.0001) was also observed for dry eye manifestations and the daily been treated with AZT. Previously, Gill et al. [25] reported a remission in adult T-cell leukaemiause of AT was rapidly reduced (P < 0.01). The benefit was confirmed by all tear gland function tests, which lymphoma related to HTLV-1 infection treated with a combination of AZT and interferon alpha. improved significantly in six of the seven patients and were unchanged in one (P < 0.02) ( Table 2) .
The mechanisms by which AZT exerts a biological action in SS remain unclear. AZT is known to be active General and extraglandular symptoms against retroviruses, but this drug could also play an immunomodulatory role [26 ] . In contrast to studies of Fatigue disappeared after treatment in all patients (P < 0.001), mostly during the second month of treathydroxychloroquine in SS [27, 28] , no fall in ESR or IgG levels in the patients was observed, suggesting that ment. Diffuse muscular pain was reduced in all but one patient. Tender points present at entry in 6/7 patients the systemic course was not affected during the short period of treatment. disappeared after treatment (P < 0.02). Accordingly, global assessments of the disease by the patient Many biases can be identified in such an open trial. We cannot rule out a placebo effect. However, it should (P < 0.001), as well as by the physician (P < 0.001), improved. Dry cough, which was present in 4/7 patients be emphasized that the beneficial effects were maintained after 1 month follow-up in 5/7 patients, contrasting with at entry, disappeared in two after the second month. Raynaud's phenomenon, which was present in 4/7 very limited placebo effect found in the other trials in SS [20] [21] [22] . A flare occurred in one patient after the patients before starting therapy, was not modified. The <10 Hamilton depression scale score at entry remained end of the study and we decided to re-introduce AZT according to the patient's wishes. All tests improved unmodified at the end of the study.
again significantly. The encouraging results of this study Laboratory parameters support the need for multicentre randomized trials of AZT in patients with primary SS. Biological parameter values did not vary significantly.
In conclusion, the present study suggests that AZT Adverse events could be a potentially beneficial and low-risk treatment for primary SS. No major adverse event occurred during the study. Minor side-effects were reported by 6/7 patients during the first month of treatment (between the second and
